Seer, Inc.
Moat Score — Seer, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Seer's engineered nanoparticle protein-capture technology is underpinned by an exclusive patent license from Brigham and Women's Hospital, a genuinely novel and legally protected technical foundation rather than an incremental improvement on existing tools. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Seer relies on Hamilton Company to manufacture its SP200 instrument and has no stated scale or cost advantage versus far larger competitors like Thermo Fisher or Danaher; a $73.6 million net loss against $16.6 million of revenue in FY2025 shows a cost structure well ahead of revenue. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | As an early-commercialization company with revenue still measured in the tens of millions, Seer has not demonstrated an ability to set or hold premium pricing against established, much larger proteomics tools vendors. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Seer's business is selling instruments and consumables to individual research customers; there is no mechanism by which additional customers make the Proteograph platform more valuable to existing users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a lab validates workflows and generates comparative datasets around the Proteograph platform and SP200 instrument, switching to a different proteomics technology requires re-validation and data-continuity costs, though the small installed base limits how broadly this lock-in currently applies. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The proteomics tools market is large (~$30 billion) and actively contested by both legacy giants (Agilent, Illumina, Thermo Fisher, Danaher) and multiple well-funded emerging rivals (Nautilus, Quanterix, Quantum-Si, Alamar), so Seer's niche is not shielded by a market too small to attract competition. |